Comments on: Fangda Advises Raynovent on Licensing Agreement with Qilu Pharmaceutical for GLP-1/GIP Dual-Target Ultra-Long-Acting Agonist RAY1225 Injection

Comments on: Fangda Advises Raynovent on Licensing Agreement with Qilu Pharmaceutical for GLP-1/GIP Dual-Target Ultra-Long-Acting Agonist RAY1225 Injection /press-release/fangda-raynovent-qilu-pharmaceutical-for-glp-1-gip-dual-target-ultra-long-acting-agonist-ray1225-injection/ Wed, 21 Jan 2026 09:40:16 +0000 hourly 1